Audited Standalone Financials of the Company for the Quarter and Year Ended on 31.03.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Godavari Drugs reported audited FY25 results with revenue from operations falling sharply to ₹113.35 crore from ₹156.71 crore in FY24, a decline of about 28%. Net profit for the year dropped to ₹4.38 crore from ₹5.55 crore, down roughly 21% YoY, though Q4 standalone profit fell more steeply to ₹89.31 lakh from ₹2.66 crore a year ago. Despite the top-line contraction, profitability margins improved meaningfully — full-year EBITDA margin expanded from around 8.8% to about 11.2%, suggesting better cost control. The statutory auditor (M/s Ayyadevara & Co.) issued an unmodified (unqualified) opinion on the results, and the company reported no loan defaults. Alongside results, the board approved the retirement of two independent directors (Mr. Syed Anis Hussain and Mrs. Vimala Behram Madon), appointed Mrs. Shilpa Bung as a new independent director, and appointed new internal, secretarial, and cost auditors.
Revenue shrinkage is a clear concern for shareholders, but the expansion in margins and a clean audit report offer some comfort. Investors should note sizeable related party loans outstanding to promoter-directors (around ₹11.77 crore in total), which warrant close watch. The 37th AGM is scheduled for August 28, 2025.